Drug Resistance to HIV-1 Integrase Inhibitors Among Treatment-Naive Patients in Beijing, China.
PMID: 35300056
2022
Pharmacogenomics and personalized medicine
Result: Additionally, the most common protease inhibitors associated mutation was Q58E (0.23%, 11/865), followed by M46I (4.05%, 5/865) and L33F (2.89%, 3/865)(as shown in Figure 2).
Detection of Gag C-terminal mutations among HIV-1 non-B subtypes in a subset of Cameroonian patients.
Introduction: Following the Stanford algorithm (mutation list), minor resistance mutations (L10F, V11I, K20TV, L23I, L33F, K43T, F53L, Q58E, A71IL, G73STCA, T74P, N83D, and L89V) are assumed to have ancillary roles such as compensation for lower efficiency of proteolysis caused by major mutations; major resistance mutations (V32I, M46IL, I47VA, G48VM, PMID: 35061671
2022
PloS one
Table: Q58E
Brief Report: Bictegravir/Emtricitabine/Tenofovir Alafenamide Efficacy in Participants With Preexisting Primary Integrase Inhibitor Resistance Through 48 Weeks of Phase 3 Clinical Trials.
PMID: 34897227
2022
Journal of acquired immune deficiency syndromes (1999)
Table: Q58E
HIV-1 molecular transmission network among sexually transmitted populations in Liaoning Province, China.
Result: Among them, 9 cases were protease inhibitor-related resistance, and the main resistance sites were L33F, V82A, Q58E, M46L, M46I; There were 4 cases of nucleoside reverse transcriptase inhibitor resistance, the main mutation sites were V75VI, K219Q, T215A, K65R; There were 5 cases of non-nucleoside reverse transcriptase inhibitor resistance, the main mutation sites were V179E, A98G, V106I, Y181C, G190S
HIV drug resistance and HIV transmission risk factors among newly diagnosed individuals in Southwest China.
Result: Individuals infected with the subtype CRF01_AE were the most likely to develop a PI-associated mutation, followed by those infected with CRF07_BC; the mutation sites primarily comprised M46V (0.35%) and Q58E (0.43%) mutations.
HIV Drug Resistance Mutations Detection by Next-Generation Sequencing during Antiretroviral Therapy Interruption in China.
Result: Drug resistance mutations (DRMs) were detected at 12 positions in the partial pol region by Sanger sequencing (Figure 1), including one in the protease (PR) region, an accessory protease inhibitor (PI)-related resistance mutation (Q58E), and eleven in the reverse transcriptase (RT) region, including one nucleotide reverse transcriptase inhibitor (NRTI)-related (M184V), and ten others were NNRTI-related.
Discussion: Four DRMs including D30N (1), M46I (2) and N88D<
Low Frequency of Integrase Inhibitor Resistance Mutations Among Therapy-Naive HIV Patients in Southeast China.
PMID: 33679129
2021
Drug design, development and therapy
Abstract: Two individuals harbored PIs-resistance mutations: Q58E in one patient and M46I, I54V, V82A, L10F, and Q58E mutations in another patient.
Result: Two patients harbored PIs-resistance mutations: Q58E mutation in one patient, 3 major mutations (M46I, I54V, V82A) and 2 accessory mutations (L10F, Q58E) in another individual (Table 2).
Table: Q58E
Correlation of HIV-1 drug resistant mutations and virologic failure.
PMID: 34584606
2021
The Pan African medical journal
Table: Q58E
Molecular Network Analysis Reveals Transmission of HIV-1 Drug-Resistant Strains Among Newly Diagnosed HIV-1 Infections in a Moderately HIV Endemic City in China.
Abstract: Molecular network analysis revealed three CRF07_BC clusters with TDR [two with Q58E (29/29) and one with K103N (10/19)]; and five CRF01_AE clusters with TDR [two with M46L (6/6), one with A98G (4/4), one with E138A (3/3), and one with K103R/V179D (3/3)].
Abstract: TDR mutations detected in more than 10 cases were Q58E (n = 51), M46ILV (n = 46), K103N (n = 26), E138AGKQ (n = 25), K103R/V179D (n = 20), and A98G (n = 12).
HIV mutation literature information.
PMID: 
2022
Pharmacogenomics and personalized medicine
Browser Board
Co-occurred Entities
Filtrator
ViMRT